---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-020977"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-18T23:43:14.318575+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Genprex reports positive preclinical data for GPX-002 using lipid nanoparticle delivery at ADA 2025

## Summary
- Nine LNPs tested; two were highly efficient in transfecting α- and β-cells in isolated mouse islets.
- LNP using ALX-184 with mRNA payload injected into mouse common bile duct efficiently transfected pancreatic cells.
- Non-viral LNP approach could enable repeat dosing and may eliminate need for immunosuppression.
- Research presented at ADA 85th Scientific Sessions in Chicago; builds on ongoing AAV-based studies.
- Company views results as proof-of-concept for a next-generation diabetes gene therapy delivery system.

## SEC filing metadata
- accession: 0001437749-25-020977
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925020977/0001437749-25-020977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925020977/gnpx20250618_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-020977
- JSON: https://secwatch.observer/filing/0001437749-25-020977.json
- Plain text: https://secwatch.observer/filing/0001437749-25-020977.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.